Sox-17 siRNA (h): sc-38429



The Power to Question

BACKGROUND

Sox genes comprise a family of genes that are related to the mammalian sex determining gene SRY. These genes similarly contain sequences that encode for the HMG-box domain, which is responsible for the sequence-specific DNA-binding activity. Sox genes encode putative transcriptional regulators implicated in the decision of cell fates during development and the control of diverse developmental processes. The highly complex group of Sox genes cluster at least 40 different loci that rapidly diverged in various animal lineages. At present, 30 Sox genes have been identified. Members of this family have been shown to be conserved during evolution and to play key roles during animal development. Some are involved in human diseases, including sex reversal.

REFERENCES

- Laudet, V., et al. 1993. Ancestry and diversity of the HMG box superfamily. Nucleic Acids Res. 21: 2493-2501.
- Kuhlbrodt, K., et al. 1998. Sox10, a novel transcriptional modulator in glial cells. J. Neurosci. 18: 237-250.
- Arsic, N., et al. 1998. Characterisation and mapping of the human Sox-14 gene. Cytogenet. Cell Genet. 83: 139-146.
- Osaki, E., et al. 1999. Identification of a novel SRY-related gene and its germ cell-specific expression. Nucleic Acids Res. 27: 2503-2510.
- Sasai, Y. 2001. Roles of Sox factors in neural determination: conserved signaling in evolution? Int. J. Dev. Biol. 45: 321-326

CHROMOSOMAL LOCATION

Genetic locus: SOX17 (human) mapping to 8q11.23.

PRODUCT

Sox-17 siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see Sox-17 shRNA Plasmid (h): sc-38429-SH and Sox-17 shRNA (h) Lentiviral Particles: sc-38429-V as alternate gene silencing products.

For independent verification of Sox-17 (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-38429A, sc-38429B and sc-38429C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNAse-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNAse-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

Sox-17 siRNA (h) is recommended for the inhibition of Sox-17 expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 µM in 66 µl. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor Sox-17 gene expression knockdown using RT-PCR Primer: Sox-17 (h)-PR: sc-38429-PR (20 μ l, 478 bp). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

SELECT PRODUCT CITATIONS

- Fu, D.Y., et al. 2010. Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer. Breast Cancer Res. Treat. 119: 601-612.
- 2. Yang, T., et al. 2014. Sox17 inhibits hepatocellular carcinoma progression by downregulation of KIF14 expression. Tumour Biol. 35: 11199-11207.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com